LianBio
As of the edition of 20 October 2026, LianBio runs 3 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Mavacamten | Ends 2036 (patent) | 0 |
| Infigratinib | Ends 2029 (patent) | 4 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| PTPN11 Tyrosine-protein phosphatase non-receptor type 11 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where LianBio needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 2 trials led
- Heart and blood vessels: 2 trials led
- Bones, joints and muscles: 1 trials led